Maze Therapeutics Secures $115 Million Series D Financing to Advance Novel Small Molecule Precision Medicines for Kidney, Cardiovascular, and Metabolic Diseases

Dec 04, 2024 10:47 CST Updated 10:47

Maze Therapeutics

Developer of Therapeutic Drugs for Genetic Diseases

December 3,South of San Francisco, California, Maze Therapeutics, a clinical-stage biopharmaceutical company leveraging the power of human genetics to develop novel small-molecule precision medicines for patients with kidney, cardiovascular, and metabolic diseases, announced the completion of a $115 million Series D financing, which included the conversion of previously issued convertible notes purchased by existing investors. The Series D financing was co-led by investors Frazier Life Sciences and Deep Track Capital. Janus Henderson Investors and Logos Capital also participated. Existing investors include Third Rock Ventures, ARCH Venture Partners, Matrix Capital Management Partners, GV, General Catalyst, Andreessen Horowitz (a16z), Foresite Capital, Woodline Partners LP, Castin Capital, Piper Heartland Healthcare Capital, Moore Strategic Ventures, and other leading existing healthcare investors. Third Rock Ventures launched Maze in 2019 with a $191 million investment, and prior to the Series D round, the biotech had raised over $400 million. Maze's last disclosed funding round of $190 million was in January 2022.

This latest funding will support the advancement of Maze’s leading programs, MZE829 and MZE782. MZE829 is an oral APOL1 inhibitor being evaluated for the treatment of APOL1 kidney disease (AKD), including patients with focal segmental glomerulosclerosis (FSGS), with a Phase 2 trial expected to begin in the first quarter of 2025. MZE782 is an oral SLC6A19 inhibitor, which Maze is evaluating in a Phase 1 trial in healthy volunteers, with plans to develop it as a treatment for chronic kidney disease (CKD) and phenylketonuria (PKU). Data from the Phase 1 clinical trial is expected to be released in the second half of 2025.

Jason Coloma, Ph.D., CEO of Maze Therapeutics, stated:"We are grateful and honored to have received continuous support from long-term investors over the past few years, and we are delighted to welcome the Frazier, Deep Track, Janus, and Logos teams as we advance our two leading clinical programs, MZE829 and MZE782, and continue to leverage our Compass platform. The additional resources provided by this financing will enable us to optimize the upcoming Phase 2 clinical trial for MZE829 and further explore the potential of these two lead programs. This financing marks a significant step forward in our development as a company and an important step for the patients we aim to serve."

James Brush, M.D., General Partner and Portfolio Manager of Frazier Life Sciences, said:"Maze Therapeutics has demonstrated impressive productivity by leveraging its platform focused on precision medicine and variant functionalization approaches. At Frazier, patient impact is at the core of our investment philosophy. We believe Maze Therapeutics is well-positioned to address the primary disease drivers for patients with CKD, AKD, FSGS, PKU, and other metabolic disorders."

Follow the official account below to see the world!